Quick Answer
ImmunityBio, Inc. reported Net Income Loss of -$351.40 million for the year ending 2025.
- ImmunityBio, Inc. showed an increase of +15.0% in Net Income Loss from 2024 to 2025.
- This data is from ImmunityBio, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$1.09 million | Q2 2014: -$1.42 million | Q3 2014: -$918.0 thousand | Q4 2014: -$2.76 million | Q1 2015: -$32.85 million | Q2 2015: -$130.89 million | Q3 2015: -$46.31 million | Q4 2015: -$26.82 million | Q1 2016: -$30.68 million | Q2 2016: -$34.00 million | Q3 2016: -$31.90 million | Q4 2016: -$24.24 million | Q1 2017: -$24.52 million | Q2 2017: -$23.45 million | Q3 2017: -$23.97 million | Q4 2017: -$24.49 million | Q1 2018: -$27.52 million | Q2 2018: -$27.73 million | Q3 2018: -$23.64 million | Q4 2018: -$17.34 million | Q1 2019: -$17.89 million | Q2 2019: -$16.68 million | Q3 2019: -$15.58 million | Q4 2019: -$15.64 million | Q1 2020: -$37.04 million | Q2 2020: -$51.44 million | Q3 2020: -$65.60 million | Q4 2020: -$32.13 million | Q1 2021: -$79.61 million | Q2 2021: -$88.29 million | Q3 2021: -$87.63 million | Q1 2022: -$102.83 million | Q2 2022: -$94.59 million | Q3 2022: -$110.94 million | Q1 2023: -$116.34 million | Q2 2023: -$137.88 million | Q3 2023: -$95.58 million | Q1 2024: -$134.11 million | Q2 2024: -$134.56 million | Q3 2024: -$85.73 million | Q1 2025: -$129.65 million | Q2 2025: -$92.56 million | Q3 2025: -$67.25 million.
- Over the full 13 years of available data (2013 to 2025), ImmunityBio, Inc.'s Net Income Loss has declined by 17,066.5%.
- Historical annual values: Fiscal year 2025: -$351.40 million | Fiscal year 2024: -$413.56 million | Fiscal year 2023: -$583.20 million | Fiscal year 2022: -$416.57 million | Fiscal year 2021: -$346.79 million | Fiscal year 2020: -$221.85 million | Fiscal year 2019: -$157.78 million | Fiscal year 2018: -$96.23 million | Fiscal year 2017: -$96.42 million | Fiscal year 2016: -$120.81 million | Fiscal year 2015: -$236.88 million | Fiscal year 2014: -$6.19 million | Fiscal year 2013: -$2.05 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: